Adrenergic Agonists and Alpha-2 Agonists in Glaucoma Management

Historical Adrenergic Agonists: Epinephrine and Dipivefrin

  • Epinephrine

    • These medications have been used for decades, beginning with epinephrine itself.
    • Epinephrine was associated with a wide range of topical and systemic side effects.
    • Systemic effects included hypertension and tachyarrhythmias.
    • Long-term use of epinephrine can lead to the formation of adrenochrome deposits. These deposits may resemble a melanotic malignancy (like melanoma) in the eye.
    • Clinicians should evaluate elderly patients with a long history of glaucoma for these lesions and inquire about prior epinephrine use.

  • Dipivefrin (Propine)

    • This is a pro-drug version of epinephrine.
    • It was developed to eliminate most systemic side effects associated with epinephrine.
    • However, it did not successfully eliminate topical side effects.

Contemporary Alpha-2 Adrenergic Agonists

  • Primary Agents

    • Modern treatment utilizes selective alpha-22 adrenergic agonists: Apraclonidine and Brimonidine.
    • While formulations and preservatives have changed over time, topical side effects remain a significant clinical problem.

  • Mechanism of Action

    • The exact mechanism is considered somewhat vague or not entirely clear.
    • These drugs function by:
      • Decreasing aqueous humor production.
      • Increasing aqueous humor outflow.
    • The speaker notes that the increased outflow is more likely occurring through the ciliary body rather than the trabecular meshwork, though this is not definitive.

Comparison with Beta Blockers and Neuroprotection

  • Efficacy vs. Beta Blockers

    • Adrenergic agonists are indicated for all forms of glaucoma.
    • Unlike beta-blockers (beta-adrenergic antagonists), which do not work well at night, adrenergic agonists remain active during nocturnal hours.

  • Neuroprotection and the LoGITT Study

    • There is some evidence regarding neuroprotection in the context of the LoGITT study for normal tension glaucoma.
    • In this study, adrenergic agonists were found to be more active than beta-blockers.
    • Animal studies have also suggested neuroprotective qualities.
    • The speaker personally finds the evidence for these as neuroprotective agents to be not entirely compelling, though they may be preferable to beta-blockers when treating normal-tension glaucoma.

Contraindications and Safety in Pediatrics

  • Contraindication in Infants

    • Brimonidine must never be used in babies or young children.
    • The medication can be fatal in this population.
    • It is known to cause respiratory arrest and profound respiratory depression.

  • Blood-Brain Barrier Considerations

    • Apraclonidine is considered safer for use in infants and young children because it does not cross the blood-brain barrier.
    • Brimonidine does cross the blood-brain barrier, leading to the aforementioned central nervous system and respiratory risks.

  • Monoamine Oxidase Inhibitors (MAOIs)

    • Alpha-adrenergic agonists are strictly contraindicated in patients currently taking monoamine oxidase inhibitors.

Side Effects and Identification

  • Topical Side Effects

    • Adrenergic agonists have the highest incidence of topical side effects compared to any other topical glaucoma medications.
    • Common reactions include:
      • Hyperemia (redness of the eye).
      • Follicular conjunctivitis: A specific follicular reaction typical of this drug class.
      • Periocular erythema (redness around the eye).
    • Profound topical allergies are common. If a patient is on multiple medications (e.g., prostaglandin, beta-blocker, alpha-agonist, and carbonic anhydrase inhibitor) and presents with a severely red/irritated eye, the alpha-agonist is usually the culprit.

  • Systemic Side Effects

    • Systemic effects are generally uncommon in adults but can include occasionally occurring somnolence (drowsiness).
    • As noted, respiratory depression is a critical risk in pediatric patients.

  • Visual Indicators

    • Adrenergic agonists are frequently identified by a purple cap on the medication bottle.

Specific Drug Profiles and Dosing

  • Apraclonidine (Iopidine)

    • Rarely used for chronic treatment because patients frequently develop sensitivity and topical reactions to it.
    • It is primarily used acutely to prevent intraocular pressure spikes following procedures such as trabeculoplasty and iridotomy.

  • Brimonidine

    • The most commonly used agent in this class today.
    • It is widely available as a generic medication in the United States.

  • Combination Drugs: Combigan

    • Combigan is a fixed-combination drug containing Brimonidine and Timolol.
    • It is critical to remember the components of combination drugs to avoid accidental administration of Brimonidine to babies.

  • Dosing Regimen

    • Both Apraclonidine and Brimonidine are typically dosed either 22 or 33 times daily.
    • Increasing frequency from twice a day to three times a day rarely provides significant extra pressure-lowering "punch."
    • At most, moving to 33 times a day might lower pressure by an additional 11 to 2 mmHg2\,mmHg, rather than a more significant jump like 5 mmHg5\,mmHg.
    • The combination drug Combigan is a twice-daily (22 times a day) agent.

Summary of Key Points

  • Adrenergic agonists affect both the production and outflow of aqueous humor.
  • They exhibit the highest rate of topical side effects among glaucoma drops.
  • Brimonidine and combination drugs containing it (like Combigan) are strictly contraindicated in infants and young children due to the risk of death/respiratory arrest.
  • Apraclonidine may be a safer alternative in young people because it does not cross the blood-brain barrier.